Preclinical Hematology R&D Solutions

Online Inquiry

First Name *

Last Name *

Business Email *

Phone

Company/Institution

Job Title

Services of Interest *

When do you expect your project to start?

Project Description

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

In Vivo Non-Genetic Anemia Models for Preclinical Hematology Research

Inquiry

At Ace Therapeutics, we specialize in preclinical contract research services with a strong focus on hematological disorders. Our in vivo non-genetic anemia models are designed to support the development and evaluation of investigational agents targeting various types of anemia. We provide comprehensive downstream services including model induction, pharmacodynamic analysis, hematologic profiling, histopathology, and more. These models are ideal for early efficacy screening, dose optimization, and mechanistic studies.

Overview of Non-Genetic Anemia Models

Non-genetic anemia models simulate anemic conditions through chemical, dietary, or radiation-induced means without relying on transgenic modifications. These models provide valuable insights into anemia pathophysiology and allow for precise evaluation of therapeutic interventions targeting red blood cell (RBC) production, survival, or function.

Model Type	Induction Method	Applications
Hemolytic Anemia Model	Phenylhydrazine (PHZ) injection	RBC destruction, oxidative stress
Iron-Deficiency Anemia (IDA) Model	Iron-deficient diet with/without bleeding	Iron metabolism, erythropoiesis stimulants
Aplastic Anemia Model	Busulfan or irradiation	Bone marrow failure, pancytopenia
Anemia of Chronic Disease (ACD)	Lipopolysaccharide (LPS) or cytokine injection	Inflammation-induced anemia
Blood Loss Anemia Model	Controlled phlebotomy or tail bleeding	Acute volume loss, RBC recovery

Key Features of Our Anemia Models

Well-Characterized Pathophysiology: Mimic distinct causes of anemia such as hemolysis, iron depletion, or inflammation.
Flexible Induction Protocols: Adjust dosing, timing, and duration to mimic acute or chronic conditions.
Translatable Endpoints: Include complete blood counts (CBC), reticulocyte levels, iron parameters, EPO quantification, bone marrow cellularity, and spleen histology.
Customizable Study Design: Tailored to the pharmacology and mechanism of your candidate molecule.
Validation with Reference Compounds: Models have been benchmarked using erythropoiesis-stimulating agents (ESAs), iron supplements, corticosteroids, and immunomodulators.

Services Offered

Ace Therapeutics delivers a full suite of preclinical services using these validated anemia models:

Preclinical Study Design and Execution

Protocol development based on drug class and target mechanism
Dose-range finding and toxicity-tolerability assessment
Disease model induction and monitoring

Pharmacodynamic & Mechanistic Evaluations

Hematologic profiling
Reticulocyte response and erythropoietic activity
Serum ferritin, transferrin saturation, and hepcidin levels
Inflammatory cytokine quantification

Tissue and Imaging Analyses

Histopathological examination of bone marrow, spleen, and liver
Prussian blue staining for iron storage
Immunohistochemistry for erythroid lineage markers
Optional imaging (MRI/spleen size, in vivo iron tracking)

Model Validation and Controls

Each model employed at Ace Therapeutics is validated with positive and negative control compounds to ensure consistency, predictability, and translational relevance. Below is a brief overview:

Model	Control Compound	Validated Readouts
PHZ-Induced Hemolytic Model	N-acetylcysteine, Prednisone	Hb restoration, RBC lifespan, spleen weight
Iron-Deficiency Model	Ferrous sulfate, EPO	Iron repletion, reticulocyte rebound, Hb rise
Aplastic Model (Busulfan)	G-CSF, Cyclosporine A	WBC, RBC recovery, bone marrow cellularity
Chronic Inflammation Model	Anti-IL-6, Dexa	Hepcidin, IL-6, serum iron, Hgb normalization
Blood Loss Model	Volume resuscitation + EPO	Hb normalization, marrow erythroid precursors

Drug Classes Suitable for Evaluation

Erythropoiesis-stimulating agents (e.g., recombinant EPO analogs)
Iron supplements (oral or IV formulations)
Iron chelators or regulators of iron homeostasis (e.g., hepcidin inhibitors)
Immunomodulators (for anemia of chronic inflammation)
Small molecules or biologics targeting RBC survival
Stem cell modulators for aplastic anemia

Ace Therapeutics is committed to providing actionable insights and high-quality preclinical data to accelerate your hematology drug development programs. Contact our scientific team to discuss your study needs and learn how our anemia models can support your pipeline.

Frequently Asked Questions (FAQs)

What animal species do you use for anemia models?

We primarily use mice and rats, depending on the study requirements, drug PK profiles, and endpoint sensitivity.

Can I customize the model parameters to reflect chronic versus acute anemia?

Yes. We provide both acute and chronic model variations. For example, chronic iron-deficiency anemia is induced through prolonged dietary restriction, while acute hemolytic anemia involves a single PHZ dose.

What endpoints are typically measured in these studies?

Key endpoints include hemoglobin levels, hematocrit, RBC count, iron indices (ferritin, serum iron), reticulocytes, cytokines, and histopathology.

Can you perform combination studies (e.g., iron + ESA)?

Yes. We can design multi-arm studies evaluating drug combinations, synergistic effects, and dose-response relationships.

Do you offer follow-up studies like PK or toxicology in the same model?

Yes. We can integrate pharmacokinetics, tolerability, or biodistribution assessments alongside the efficacy study.